Summary: Inhibitors of apoptosis and of excitotoxic cell death reduce brain damage after transient and permanent middle cerebral artery occlusion. We compared the neuropro tective effects of two caspase family inhibitors with the N methyl-D-aspartate receptor antagonist (+)-MK-801 hydrogen maleate (MK-80 I) in a newly characterized cycloheximide sensitive murine model of transient middle cerebral artery oc clusion (30 minutes) in which apoptotic cell death is prominent. Ischemic infarction, undetected by 2,3,5-triphenyltetrazolium chloride staining at 24-hour reperfusion, featured prominently in the striatum at 72 hours and 7 days on hematoxylin-eosin stained sections. Markers of apoptosis, such as oligonucleo somal DNA damage (laddering) and terminal deoxynucleo tidyl transferase-mediated dUTP-biotin nick-end labeling (TUNEL)-positive cells first appeared at 24 hours and in creased significantly at 72 hours and 7 days after reperfusion. The TUNEL-labeled cells were mostly neurons and stained negative for glial (GFAP, glial fibrillary acid protein) and leu kocyte specific markers (CD-4S). The caspase inhibitors, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (z VAD.FMK; 120 ng intracerebroventricularly) or N benzyloxycarbonyl-Asp-Glu-Val-Asp-t1uoromethyl ketone (z DEVD.FMK; 480 ng intracerebroventricularly) decreased in farct size and neurologic deficits when administered 6 hours 
after reperfusion. The extent of protection was greater than in models of more prolonged ischemia or after permanent occlu sion, and the therapeutic window was extended from 0 to 1 hours after 2-hour middle cerebral artery occlusion to at least 6 hours after brief ischemia. Also, z-V AD.FMK and z DEVD.FMK treatment decreased oligonuc1eosomal DNA damage (DNA laddering) as assessed by quantitative autoradi ography after gel electrophoresis. By contrast, MK-80 I pro tected brain tissue only when given before ischemia (3 mg/kg intraperitoneally), but not at 3 or 6 hours after reperfusion. Despite a decrease in infarct size after MK-80 I pretreatment, the amount of DNA laddering did not decrease 72 hours after reperfusion, thereby suggesting a mechanism distinct from in hibition of apoptosis. Hence, 30 minutes of reversible ischemia augments apoptotic cell death, which can be attenuated by de layed z-VAD.FMK and z-DEVD.FMK administration with preservation of neurologic function. By contrast, the therapeu tic window for MK-80l does not extend beyond the time of occlusion, probably because its primary mechanism of action does not block the development of apoptotic cell death. Key Words: interleukin-I [) converting enzyme family caspases Apoptosis-Cerebral ischemia-Delayed neuronal death Mice.
Several laboratories provide evidence for cell death by an apoptotic mechanism in animal models of cerebral ischemia (Li et aL, 1995a,b,c; MacManus et ai., 1995a,b; Charriaut-Marlangue et ai., 1996) . Apoptosis is a cell suicide program under active cell control. The interleu kin-l 13 converting enzyme (ICE) family caspases, impli cated in apoptotic cell death (Yuan and Horvitz, 1990; Ellis et aI., 1991) , are the human homologues of the nematode Caenorhabditis elegans CED-3. Eleven mem bers of this family have been identified, which share a common QACXG consensus sequence (Alnemri et aI., 1996) . Caspase I (ICE) cleaves a pro-interleukin-I 13 31-kilodalton (kd) protein to generate mature 17.5-kd inter leukin-I13, which is involved in inflammatory reactions (Dinarello, 1994) , apoptosis (Friedlander et aI., 1996) , as well as focal and global cerebral ischemia (Saito et aI., 1996; Liu et aI., 1993) . Caspase 3 (CPP32), another im portant family member implicated in apoptotic cell death, cleaves poly(ADP-ribose)polymerase and DNA dependent protein kinase delta, among other substrates (Tewari et al., 1995; Nicholson et aI., 1995) .
Reports from our laboratory show that peptide inhibi tors of the caspase family (N-benzyloxycarbonyl-Val Ala-Asp-fluoromethyl ketone [z-V AD.FMKJ and N benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethyl ke tone [z-DEVD.FMK]) are neuroprotective after focal reversible cerebral ischemia in mice and rats (Hara et aI., 1997a) . Both drugs reduced tissue injury and associated neurologic deficits after 2-hour middle cerebral artery occlusion (MCAO) when assessed at 24 and 72 hours (Hara et aI., 1997 a) . Interleukin-l!3 formation, a product of ICE cleavage, was significantly blocked by z V AD.FMK, a rather unselective caspase inhibitor, but not by the putative caspase 3 inhibitor z-DEVD.FMK. Smaller infarcts also were observed in transgenic mice expressing a dominant negative mutation of ICE (Fried lander et al., 1997; Hara et aI., 1997 b) . Cleavage of pro interleukin-l!3 is important to the development of isch emic damage (Relton and Rothwell, 1992; Yamasaki et al., 1995) as is a cascade that may involve activation of caspase 3. We speculated that an important mechanism by which z-VAD and z-DEVD decrease infarct size re lates to blockade of ischemia-induced apoptosis and in this report, we tested the effects of peptide methyl ketones in a murine model of brief (30 minutes) transient focal cerebral ischemia.
Mild injury augments apoptotic cell death in in vitro and in vivo models of cell injury, including brain isch emia. In the rat, infarct development is delayed until 3 days after 30 minutes of distal middle cerebral artery occlusion whereas tissue damage develops much earlier (within 24 hours) after 90 minutes or 2 hours of revers ible MCAO. In this rat model, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) positive cells and laddered DNA are present in the peri infarct zone, suggesting a role for apoptotic cell death (Du et al., 1996) .
In the current study, we developed a model of mild ischemia in mice showing delayed infarct development and delayed appearance of several apoptosis markers (TUNEL staining, DNA laddering). We then evaluated the efficacy and the treatment window of two caspase inhibitors. We determined whether inhibition of caspase family members by the use of peptide methylketones decreases DNA laddering in ischemic tissue as measured by densitometry on agarose gels. Delayed therapeutic intervention-possibly directed against apoptotic death-may become an important therapeutic strategy to reduce mild ischemic insults (Du et al., 1996) .
METHODS

Drugs
Both z-VAD.FMK and z-DEVD.FMK were obtained from Enzyme Systems Products (Dublin, CA, U.S.A. 
Physiology
Regional cerebral blood flow (rCBF) was measured by La ser-Doppler flowmetry (PF2B, Perimed, Stockholm, Sweden) along with arterial blood pressure and heart rate as described (Hara et aI., 1996 (Hara et aI., , 1997 . Arterial blood samples (50 fLL) were analyzed for pH, oxygen (Pa0 2 ), and carbon dioxide (Paco 2 ) using a blood gas/pH analyzer (Corning 17S, Ciba Corning Diagnostics, Medford, MA, U.S.A.). Core temperature was maintained at 36.5° ± 1°C with a temperature control unit (FHC, Brunswick, ME, U.S.A.) and a heating lamp (Skytron, Daiichi Shomei, Tokyo, Japan) until 1 hour after reperfusion and during the treatment and monitoring period. With the ex ception of MK-SOI experiments (see treatment protocol), ani mals were kept at room temperature during the reperfusion period. For physiologic monitoring, animals (selected ran domly) were monitored for rCBF and physiologic parameters before and during ischemia, and until 30 minutes after reper fusion for different reperfusion protocols (24 and 72 hours; n = 4 per group). In an earlier study, we determined that intra cerebroventricular pretreatment with peptide methylketones had no obvious effects on rCBF, mean arterial blood pressure, heart rate, core temperature, and arterial blood gases (Hara et aI., 1 997a).
Ischemia model
Adult male 129/SV mice (IS to 20 g, Taconic farms, Ger mantown, NY, U.S.A.) were anesthetized with 1.5% halothane for induction and maintained on 1.0% halothane in 70% N 2 0 and 30% O 2 using a Fluotec 3 vaporizer (Colonial Medical, Amherst, NH, U.S.A.). Ischemia was induced with a S.O nylon monofilament coated with silicone resin/hardener mixture (Xantopren and Elastomer Activator, Bayer Dental, Osaka, Ja pan), as described previously (Hara et aI., 1996) . The filament was introduced into the left internal carotid artery up to the anterior cerebral artery. For filament withdrawal, the animals were briefly reanesthetized. The MCAO procedures were per formed by two investigators (M. E. examined the effects of z-VAD.FMK and MK-SOI experiments, whereas M. S. -So tested z-DEVD.FMK).
Treatment protocol
Both z-V AD.FMK (120 ng) and z-DEVD.FMK (160 ng or 4S0 ng) were injected intracerebroventricularly (2 fLL; bregma -0.9 mm lateral, -0.1 mm posterior, -3.1 mm deep) either 10 minutes before ischemia or 6, 12, or IS hours after reperfusion. Control animals were injected with 2 fLL of 0.3% DMSO. Cycloheximide (10 mg/kg) was administered intraperitoneally I day before ischemia. MK-SOI (3 mg/kg) was administered intraperitoneally 10 minutes before ischemia or 3 or 6 hours after reperfusion. Control animals were injected intraperito neally with a corresponding volume of PBS. Since hypothermia is a well known consequence of MK-SOI treatment, animals were kept in an incubator (TherrnoCare System, Incline Vil lage, NV, U.S.A.) at 30 to 31°C for 6 hours after treatment to maintain a body temperature of 37°C. Core temperatures were measured using a thermometer (BAT-12, Physitemp, Clifton, NJ, U.S.A.) after 3 and 6 hours. Control mice (36.So ± 0.2°C at 3 hours and 36.7° ± 0.2°C at 6 hours) did not differ from MK-801-injected animals (36.70 ± O.loC at 3 hours and 36.7" ± 0.2DC at 6 hours).
Infarct measurement
For survival longer than 24 hours, infarct size was measured from hematoxylin-eosin (H&E)-stained sections, whereas tri phenyltetrazolium chloride (TTC; Sigma, St. Louis, MO, U.S.A.) stained 2-mm coronal sections were used to assess injury after shorter periods of occlusion. For H&E-stained sec tions, the brains were first immediately frozen in 2-methyl butane on dry ice and then sectioned. For TTC staining, animals were decapitated, and the brains were divided into five coronal 2-mm sections using a mouse brain matrix (RBM-2000C, Activational Systems, MI, U.S.A.) and stained with 2% 2,3,5-TTC. Infarction volume was quantitated in TTC-stained sections or in H&E-stained cryostat section (12 /-Lm) with an image analysis system (M4, Imaging Research, St. Catherines, Ontario, Canada) and calculated by summing the volumes of each section determined directly (Huang et aI., 1994) or indi rectly using the following formula: contralateral hemisphere (in cubic millimeters) minus undamaged ipsilateral hemisphere (in cubic millimeters) (Swanson et aI., 1990) . Differences between "direct" and "indirect" volumes are likely to be accounted for by brain swelling.
Neurologic deficits
Mice were tested for neurologic deficits and scored as de scribed by Bederson and others (1986) with the following mi nor modifications (Hara et aI., 1996) : 0, no observable neuro logic deficit (normal); I, failure to extent right forepaw (mild); 2, circling to the contralateral side (moderate); 3, loss of walk ing or righting reflex (severe). The rater was naive to the treat ment protocol and to the group's identity. Assessments were made at 30 minutes after onset of ischemia and 24 and 72 hours (if necessary) after reperfusion.
DNA analysis
Samples were obtained at different time points after 30 min utes of transient MCAO. Ischemic striatal tissue was taken from the third 2-mm section along with homologous tissue from contralateral side after the brain was cut coronally with a brain matrix. For quantitation of DNA damage, a terminal transferase-dependent e2p]ddATP end-labeling method was used (Tilly and Hsueh, 1993) with minor modifications, as described previously (Hara et aI., 1997 h) . Three micrograms of DNA were used in the labeling procedure together with 35 ng of a 100-base pair (bp) DNA fragment as an internal standard. Electrophoresis was performed on the DNA on a 2.0% agarose gel (agarose 3:1, Amresco, Solon, OH, U.S.A.), autoradio graphed together with a e 2 pJ standard, and analyzed with the M4 image analysis system. DNA less than 10 kb was used as an index of total DNA fragmentation. To measure oligonucleo somal damage more specifically, laddered DNA less than 1000 bp was measured by summing the areas of each peak (areas under the curve) minus baseline densitometry readings. The method of quantitation was validated using an artificial "smear-ladder" system in which smeared DNA was extracted from a decapitated mouse brain and incubated at 37DC for 48 hours (MacManus et aI., 1995h) . In a total amount of I /-Lg of DNA, 0.02, 0.04, 0.08, and 0.12 /-Lg of a commercially avail able 200-bp ladder (Invitrogen, Carlsbad, CA, U.S.A.) were added to a constant amount of smeared DNA (Fig. I) . In an other experiment, increasing amounts of smeared DNA (0.3, 0.5, 0.7, 0.9 /-Lg) were added to a constant amount of ladder (0.1 /-Lg). The measurements for "total DNA fragmentation" and
"DNA laddering" were related linearly to the amount of total (smeared) and laddered DNA (error < 10%).
Terminal deoxynucIeotidyl transferase-mediated dUTP nick-end labeling
The TUNEL staining was carried out according to the method of Gavrieli and others (1992) with minor modifications according to Wood and associates (1993) . Terminal deoxy nucleotidyl transferase and biotinylated dUTP were obtained from Boehringer Mannheim (Mannheim, Germany). The bio tinylated dUTP was visualized by the avidin-biotin method with 3' -3' diaminobenzidine as chromogene. The reaction was intensified with 0.04% nickel chloride. For negative controls, either terminal deoxynUcleotidyl transferase or biotinylated dUTP was omitted. For positive controls, the sections were treated with DNase 1.
For cell counts, sections were counterstained lightly with H&E. Following a systematically random sampling scheme and based on stereologic techniques (Gundersen, 1992; West, 1993; Gomez-Isla et aI., 1996) , five coronal sections (12 /-Lm) were selected, taken at equally spaced intervals (2 mm) through the full rostrocaudal extent of the brain. The boundaries of the area occupied by TUNEL-positive cells within each section were marked using the Bioquant Image analysis system (Nashville, TN, U.S.A.). The entire volume of the lesion occupied by TUNEL-positive cells was calculated according to the principle of Cavalieri (Cavalieri, 1966) . Within each section with TUNEL-positive cells, a systematically random sampling scheme was applied to count cells. The total number of TUNEL-positive cells in each brain was estimated by using -80 optical dissectors and a 40 x objective. Each optical dis sector was a 100 x 100 /-Lm sampling box with extended ex clusion edges. The appropriateness of the sampling scheme chosen was evaluated by calculating the precision of the esti mates in each animal, expressed as the coefficient of error (West and Gundersen, 1990) . In all cases, the coefficient of error was less than 0.10, suggesting that a minimal amount of variance in the counts can be attributed to the technique. The calculation of total number of TUNEL-positive cells was per formed by multiplying the volume density of TUNEL-positive cells by the total volume occupied by TUNEL-positive stain ing.
Glial fibrillary acid protein immunohistochemistry/ TUNEL double staining and CD-45 (leukocyte common antigen) immunohistochemistry
Glial fibrillary acid protein (GFAP)/TUNEL double staining was performed to determine if glial cells show TUNEL stain ing. The TUNEL staining protocol was performed as described earlier. Subsequently, sections were washed and blocked with 10% normal goat serum in PBS. GFAP double labeling was performed with a rabbit GFAP polyclonal antibody (1 :500, Dako Corporation, Carpintiera, CA, U.S.A.) using a three-stage avidin-biotin method and biotinylated goat anti-rabbit IgG as secondary antibody. The reaction product was visualized with 3-amino-9-ethylcarbazole reagent (Elite PK 6101 Kit, Vector Laboratories, Burlingame, CA, U,S.A.). For controls, single GFAP immunostaining was performed in adjacent sections.
To identify inflammatory cells, CD-45 (leukocyte common antigen) immunohistochemical study was performed on adja cent sections with a purified rat anti-mouse antibody (I :500, Clone 30FI1.I, Pharmingen, San Diego, CA, U.S.A.) and a three-stage avidin-biotin method with a biotinylated rabbit anti-rat IgG (BA 4001, Vector Laboratories) as secondary an tibody.
A.
Densitometry readings before (top) and after (bottom) baseline subtraction 
Statistical analysis
Data are presented as mean ± SD. Statistical comparisons were made by one-way analysis of variance and followed by Dunnett test (rCBF) or Tukey test (physiology). For neurologic deficits, Mann-Whitney rank sum test was applied for two groups, and Kruskal-Wallis one-way analysis of variance on ranks followed by Dunn test for three or more groups. For unpaired data (infarction volume and area, DNA laddering, cell counts) two-tailed Student's t test was applied. Analysis was made using the software SigmaStat (Jandel Corporation, San Rafael, CA, U.S.A.) or. Excel (Microsoft, Redmond, W A, U.S.A.). P < 0.05 was considered statistically significant.
RESULTS
Mouse model of mild focal cerebral ischemia
Physiologic parameters before, during, and after isch emia were within the normal range and did not differ between groups. Mean arterial blood pressure remained stable at 110 ± 12 mm Hg, and heart rate at 480 ± 70 beats per minute. Blood gases were stable at pH 7.4 ± 0. 1, Paco2 at 45 ± 5 mm Hg, and Pao2 at 125 ± 25 mm Hg. After MCAO, rCBF decreased to 20% of baseline (20% ± 8%) and was sustained during 30 minutes of ischemia. The rCBF immediately returned to more than 100% of baseline (116% ± 20%) after suture removal.
No evidence for injury was detected 24 or 72 hours (TTC staining) after 10 minutes of MCAO in pilot ex periments (n = 5 each). Twenty-four hours after 30 min utes of MCAO, ischemic changes were not detected by TIC (n = 5) or grossly by H&E (n = 5), although infrequent striatal cells showed light microscopic changes consistent with ischemia.
At 72 hours of reperfusion after 30 minutes of MCAO, clear evidence for infarction was found. Infarct size was 32.7 ± 8.3 mm 3 (n = 17) after vehicle (DMSO) was injected intracerebroventricularly 6 hours after reperfu sion. Vehicle injection did not alter infarct size, since noninjected animals showed the same injury volume (3 1.4 ± 19.2 mm 3 , n = 12). The lesion was located Time refers to drug injection after reperfusion except when noted for z-DEVD.FMK and MK-801 (given 10 minutes before MCA occlu sion). z-VAD.FMK (120 ng) and z-DEVD.FMK (480 ng) were admin istered intracerebroventricularly, MK-801 (3 mg/kg) was given intra peritoneally. Data are presented as mean ± SD. * P < 0.01 versus vehicle group. t MK-801/vehicle-treated mice were held at a constant temperature (31°C) for 6 hours after treatment.
predominantly in the striatum where cells were severely pyknotic. Cortical injury, by comparison, was minor. Le sion volume did not increase significantly by 7 days (33.5 ± 21.1 mm 3 , n = 8, no intracerebroventricular injection), and brain swelling did not contribute signifi cantly to infarct size, as assessed by an indirect method for measurement of infarct size. Cycloheximide (Chex) pretreatment (10 mglkg, n = 7) reduced infarct size (10.5 ± 9.0 mm 3 versus 31.4 ± 19.2 mm 3 , P < 0.05) at 72 hours, suggesting the importance of protein synthesis in hibition.
Inhibitors of the caspase family reduce infarct size Table 1 contains the data for experiments using caspase inhibitors and MK-80 l. Infarct size in vehicle treated controls were smaller in the z-DEVD.FMK ex periments (22.6 to 26.5 mm 3 ) versus the other two ve hicle groups (27.1 to 38.1 mm 3 ), probably because the z-V AD.FMK (120 ng) or vehicle were administered intracerebro ventricularly in a volume of 2 fl.L 6 hours after reperfusion following 30 minutes of MCAO. Mean arterial blood pressure (MABP, in mm Hg) was measured before and until 1 hour after drug injection. Fifty microliter blood was withdrawn 30 minutes after drug administration. Paco2 and Pa02 are given in mm Hg. Data represent mean ± SD (n = 5-6). There are no significant differences between groups.
surgical procedure for z-DEVD.FMK was performed by a different investigator (see Methods),
A dose of z-VAD.FMK (120 ng intracerebroventricu larly) given 6 hours after reperfusion decreased infarct size (Table 1) and neurologic deficits at 72 hours (l.0 ± 0.9 versus 2.4 ± 0.9, P < 0.05). The protective effects sustained for at least 7 days (Table 1) . When given at 18 hours after reperfusion, however, the drug was not ef fective in reducing gross infarct size (Table 1) ; neuro logic deficits did show some improvements in this group, however (1.2 ± 0.8 versus 2.4 ± 0.9).
A dose of z-DEVD.FMK (480 ng given intracerebro- Mean arterial blood pressure (MABP, in mm Hg) and heart rate (HR) were measured before, during and until 30 min after ischemia. Core temperature (CT, in 0c) was measured before and until 30 minutes after ischemia and again after 71 hours, just before sacrifice. Fifty microliter blood was withdrawn twice, before ischemia and 30 minutes after reperfusion. Paco2 and Pao2 are given in mm Hg. rCBF was measured by Laser-Doppler-flowmetry (expressed as % of baseline). z DEVD.FMK (480 ng) or vehicle were administered intracerebroven tricularly in a volume of 2 fl.L 10 minutes before ischemia (n = 5 each). Data represent mean ± SD. There are no significant differences between groups.
ventricularly 10 minutes before ischemia) significantly reduced infarction volume at 72 hours (Table 1) . A lower dose (160 ng) did not reach statistical significance (1S.0 ± 3.3 mm 3 versus 24.7 ± 5.0 mm 3 , n = 7). Infarct size and neurologic deficits (0.4 ± 0.5 versus 1.7 ± 0.5, P < 0.05) were reduced when 4S0 ng z-DEVD.FMK was administered at 6 hours after reperfusion (Table I) . In farct volumes, although decreased, did not reach statis tical significance when z-DEVD was given 12 hours af ter reperfusion (Table I) .
The rCBF during ischemia and after reperfusion did not differ between groups (Tables 2 and 4 ). There were also no significant group differences in physiologic pa rameters after z-VAD.FMK (Table 3) or z-DEVD.FMK treatment (Table 4) .
Treatment with MK-SOI significantly reduced infarct size if given before MCAO but not when given 3 or 6 hours after reperfusion (Tables 2 and 3 ). Neurologic defi cits tended to be lower after pretreatment but did not differ from controls when MK-SOI was given at 3 or 6 hours after reperfusion (0.4 ± 0.6 [pretreatment], 1.0 ± O.S [3 hours], 1.2 ± O.S [6 hours] versus 1.0 ± 0.7 [con trol], n = 4 to 5 per group).
DNA fragmentation
The TUNEL-positive cells, present in low numbers throughout the striatum at 24 hours, profoundly in creased at 72 hours. The TUNEL-positive cells were identified morphologically as neurons, many of them with nuclear condensation and apopoptic bodies. Almost no TUNEL-positive cells contained GFAP double stain ing (Fig. 2 , n = 3 for each time point). At 72 hours, low numbers of CD-45-positive inflammatory cells were found within the vasculature; however, only single cells were located within ischemic brain tissue (not shown).
Laddered DNA, detected first at 24 hours, increased l6-fold at 72 hours and 46-fold at 7 days compared with 24 hours (Fig. 3 , n = 3 per group). DNA damage was already present at 6 hours as smeared DNA and increased substantially between 24 and 72 hours (Fig 3) . Total DNA damage and laddering were significantly inhibited at 72 hours by Chex pretreatment (Figs. 3 and 4) .
To test the hypothesis that caspase inhibitors block Quantitation of "DNA damage" (top) and "DNA laddering" (bottom) was perlormed as described in Fig. 1 . Laddering was first visible after 24 hours and increased by 72 hours (16-fold) and 7 days (46-fold). Each group represents the mean ± SO of three animals from independent labeling procedures.
apoptosis after ischemia, we compared the number of TUNEL-positive cells in z-V AD.FMK-treated animals (120 ng, given at 6 hours, n = 4) versus DMSO (n = 4) at 72 hours. Total number of TUNEL-positive cells was significantly reduced in the treatment group (540,000 ± 258,000 versus 1,390,000 ± 446,000, P < 0.05), and the lesion volume containing TUNEL-positive cells was re duced by 60%. The density of TUNEL-positive cells did not decrease, however (82,700/mm 3 ± 6500/mm 3 versus 84,900/mm 3 ± 9200/mm 3 ).
A significant reduction in total DNA fragmentation and DNA laddering within ischemic tissue was found at 72 hours in z-VAD.FMK-treated (n = 4) and z DEVD.FMK-treated (n = 5) animals (administered 6 hours after reperfusion) compared with controls (n = 9) (Figs. 4 and 5), whereas MK-801 pretreatment (3 mg/kg, n = 4) did not reduce DNA fragmentation or DNA laddering compared with saline-injected controls (n = 4) (Figs. 4 and 5 ).
DISCUSSION
We provide evidence for the importance of apoptosis to the delayed development of tissue injury after mild J Cereb Blood Flow Metab, Vol. 18. No. 3, 1998 focal cerebral ischemia (30 minutes of MCAO) in the mouse. In this model, ischemic brain damage became grossly visible at 72 hours and did not expand at 7 days after reperfusion. The TUNEL-positive cells and DNA laddering were observed first 24 hours after reperfusion. Cells staining TUNEL-positive probably were neurons, since they did not stain positive for GFAP or CD-45. In fact, Li and colleagues (1995a,b) came to a similar con clusion, since they found GFAP co-staining in only a few TUNEL-positive cells (10%) after 2 hours of MCAO in the rat. Treatment with inhibitors of apoptosis such as cycloheximide, z-V AD.FMK, or z-DEVD.FMK reduced ischemic injury after 30 minutes of MCAO, and peptide methylketones were more effective after mild (30 min utes) than after more prolonged ischemia (2 hours of MCAO). In the 30-minute model, z-V AD.FMK and z DEVD.FMK decreased infarct volume by 70% and 57%, respectively, whereas the degree of protection was 45% and 35%, respectively, after 2-hour MCAO (Hara et aI., 1997a; Moskowitz and Ma, 1997) . Peptide methylk etones also were more successful many hours (6 hours) after 30 minutes of MCAO compared with 0 to I hours after more prolonged (2 hours) MCAO (Hara et 1997a; Moskowitz and Ma, 1997) . Hence, mild focal cerebral ischemia provides a useful experimental tool to assess the contribution of apoptosis to delayed mecha nisms of cell death. DNA 1addering may reflect the consequences of a spe cific cascade promoting tissue injury after ischemia, which is distinct from necrosis. We found that oligo nucleosomal damage was a useful indicator of apoptotic cell death and that a newly developed method for quan titation was reliable and reproducible. A linear relation was found between the amount of laddered DNA used in the labeling procedure and the densitometry readings in validation experiments (Fig. 1) . Decreases in laddered DNA did not always accompany decreases in infarct size but depended on whether apoptosis was inhibited. For example, MK-80 l pretreatment decreased ischemic dam age but not DNA laddering (Figs. 4 and 5) . Similar find ings were observed after administering 3-amino benzamide, a widely-used inhibitor of poly(ADP ribose )polymerase . On the other hand, inhibitors of apoptotic cell death such as cyclohex imide, z-V AD.FMK, or z-DEVD.FMK clearly inhibited oligonucleosomal DNA damage and decreased infarct size (Figs. 3 through 5; Table 1 ).
The protective mechanisms of peptide methylketones and MK-801 are different. As observed, MK-80 l did not decrease DNA laddering, and its therapeutic window was relatively short in mild ischemia when apoptotic cell death is prominent. We infer that apoptosis probably is not the predominant mechanism of cell death after N methyl-D-aspartate (NMDA) excitotoxicity. Not surpris ingly then, z-V AD.FMK and z-DEVD.FMK blocked damage induced by intrastriatal NMDA microinjections only weakly (Hara et al., 1997a) . Moreover, TUNEL staining and DNA laddering appear late (24 to 48 hours) after NMDA microinjections (Ayata et al., 1997) , sug gesting that apoptosis was not primarily a direct NMDA induced event. Nevertheless, pretreatment with MK-801 protected brain in mild ischemia, suggesting that delayed ischemic death contains both necrotic and apoptotic . Because injury is slowly evolving, and MK-801 reduced infarct size when given as a pretreatment, it must mean that NMDA receptor activation initiates early (within 3 hours) a de layed mechanism of ischemic cell death that is not ex clusively apoptosis (DNA laddering does not decrease) and cannot be inhibited by blocking the NMDA receptor after the fact. The literature supports the notion that MK-801 and caspase inhibitors act through distinct yet complemen tary and synergistic mechanisms. Choi and colleagues found that NMDA receptor antagonists unmask apopto sis after oxygen-glucose deprivation in neuronal cell cul tures in vitro. Caspase inhibitors are protective in culture only after MK-80 l pretreatment (Gwag et al., 1995) . In vivo, we demonstrated synergistic protective effects after treatment with MK-801 plus caspase inhibitors . A 35% decrease in infarct size was observed in a mouse model of focal ischemia after combining doses and treatment times when neither compound provided protection alone.
Both the mouse and rat model (30 minutes of isch emia) (Du et aI, 1996) show delayed infarct develop ment, prominent DNA laddering, and TUNEL-stained cells. Damage in the mouse, however, was primarily within striatum, whereas injury was mostly within cortex in the rat model. Additionally, the lesion in the mouse did not expand after 3 days as it did in the rat. These differences may relate to greater collateral blood flow in the mouse, as well as differences in vascular anatomy or suture placement, with attendant differences in blood flow reduction. Cycloheximide reduced injury in both species, emphasizing the importance of protein synthe- sis. The ability of cycloheximide to inhibit apoptosis is well documented in ischemia (Linnik et al., 1993; Du et aI, 1996) . Cycloheximide may at the same time increase bcl-2 expression, which also would reduce tissue injury (Furukawa et al., 1997) . In general, cycloheximide sup presses synthesis of all proteins, including those that may afford neuroprotection (e.g., superoxide dismutase, growth factors). Hence, it may be difficult to predict the effects of cycloheximide on tissue injury. In our studies, we demonstrate the relevance of caspases to injury de velopment in a model in which cycloheximide reduces infarct size. Our data could have important implications for the treatment of stroke or other evolving CNS injuries in humans, or even for procedures that carry a risk of brain damage (e.g., neurosurgical procedures or cardiopulmo nary bypass). Caspase inhibitors administered at rela tively late time points after mild brain injury or ischemia may protect injured tissue. We conclude that inhibitors of ICE family caspases might become valuable drugs to treat stroke in humans.
